Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-12-07
2010-12-28
Saoud, Christine J (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S007210, C435S368000, C435S366000, C424S009100
Reexamination Certificate
active
07858578
ABSTRACT:
Fucose galactose carbohydrates have been shown to induce neuronal outgrowth. The invention includes methods of inducing neuronal outgrowth using carbohydrates, assemblies, and polymers bearing fucose-galactose moieties, as well as associated proteins. Cell growth can be stimulated in cells in culture or in cells within an animal or patient. Growth stimulation has application to understanding and treatment of neurodegenerative diseases including, for example, Parkinson's disease, Alzheimer's disease and multiple sclerosis and conditions such as stroke, brain injury and spinal cord injury. Such compounds, polymers, and assemblies also can be used to increase neural stem or progenitor cells in culture or in an animal, and to enervate engineered tissue.
REFERENCES:
The definition of lectin in the Stedman's Medical Dictionary 27th edition, (1 page).
Smalla et al. NeuroReport. 1998. 9:813-817.
Walsh et al. Annu. Rev. Cell Dev. Biol. 1997. 13: 425-56.
Luthi et al. J. Neurochem. 1991. 56: 1493-1498.
,Berezovskaya et al. J. Neurosci. Res. 1995. 42: 192-8.
Farmer et al. J. Neurobiol. 1992. 23: 354-63.
Ducray et al. Neurosci. Lett. 1999. 274: 17-20.
Ngasaki et al. Biomacromelecules. 2001. 2:1067-1070.
Kim et al. J. Neurosci. 2003, 23: 10703-10709.
Shin et al. Exp. Mol. Med. Dec. 31, 2002; 34: 401-410.
Ferreira et al. Molecular Medicine, 1998. 4: 22-28.
Alonso et al., “Lectin histochemistry shows fucosylated glycoconjugates in the primordial germ cells of Xenopus embryos,” J. Histochem. Cytochem. (2003) 51:239-243.
Brown et al., “Combining chondrocytes and smooth muscle cells to engineer hybrid soft tissue constructs,” Tissue Engr. (2000) 6:297-305.
Bullock et al., “Effect of the amnesic agent, 2-deoxygalactose, on incorporation of fucose into chick brain glycoproteins,” J. Neurochem. (1990) 54:135-142.
Daly and Ziff, “Post-transcriptional regulation of synaptic vesicle protein expression and the developmental control of synaptic vesicle formation,” J. Neurosci. (1997) 17:2365-2375.
Gill et al., “Direct brain infusion of glial cell line-derived neurotropic factor in Parkinson disease,” Nature Med. (2003) 9:589-595.
Haselhorst et al., “Molecular recognition of sialyl LewisXand related saccarides by two lectins,” J. Am. Chem. Soc. (2001) 123:10705-10714.
Hilfiker et al., “Synapsis as regulators of neurotransmitter release,” Phil. Trans. R. Soc. London B (1999) 354:269-279.
Holden et al., “Structure and function of enzymes of enzymes of the Leloir pathway for galactose metabolism,” J. Biol. Chem. (2003) 278:43885-43888.
Horch et al., “Cultured human keratinocytes on type I collagen membranes to reconstitute the epidermis,” Tissue Engr. (2000) 6:53-67.
Huttner et al., “Synapsin I (Protein I), a nerve terminal-specific phosphoprotein. III. Association with synaptic vesicles studied in a highly purified synaptic vesicle preparation,” J. Cell. Biol. (1983) 96:1374-1388.
Jork et al., “Monoclonal antibody specific for histo-blood group antigens H (types 2 and 4) interferes with long-term memory formation in rats,” Neurosci. Res. Comm. (1991) 8:21-27.
Jork et al., “Identification of Rat Hippocampal Glycoproteins Showing Changed Fucosylation Following 2-deoxy-d-galactose-induced amnesia in a brightness discrimination task,” Neurosci. Res. Comm. (1989) 5:105-110.
Kao et al., “A third member of the synapsin gene family,” Proc. Natl. Acad. Sci. USA (1998) 95:4667-4672.
Karsten et al., “A new monoclonal antibody (A46-B/B10) highly specific for the blood group H type 2 epitope: generation, epitope analysis, serological and histological evaluation,” Br. J. Cancer (1988) 58:176-181.
Krug et al., “The amnesic substance 2-deoxy-D-galactose suppresses the maintenance of hippocampal LTP,” Brain Res. (1991) 540:237-242.
Lorenzini et al., “2-Deoxy-D-galactose effects on passive avoidance memorization in the rat” Neurobiol. Learn. Mem. (1997) 68:317-324.
Matsui et al., “Surface glycosyltransferase activities during development of neuronal cell cultures,” J. Neurochem. (1986) 46:144-150.
Matthies et al., “Fucose and fucosylgalactose enhance in vitro hippocampal long-term potentiation,” Brain Res. (1996) 725:276-280.
McCabe et al., “Passive avoidance training increases fucose incorporation into glycoproteins in chick forebrain slices in vitro,” Neurochem. Res. (1985) 10:1083-1095.
Pohle et al., “Incorporation of [3H] fucose in rat hippocampal structures after conditioning by perforant path stimulation and after LTP-producing tetanization,” Brain Res. (1987) 410:245-256.
Popov et al., “Changes in activities of fucokinase and fucosyltransferase in rat hippocampus after acquisition of a brightness discrimination reaction,” Pharmacol. Biochem. Behav. (1983) 19:43-47.
Rose et al., “Long term memory formation in chicks is blocked by 2-deoxygalactose, a fucose analog,” Behav. Neural Biol. (1987) 48:246-258.
Ryan et al., “Synaptic vesicle recycling in syapsin I knock-out mice,” J. Cell. Biol. (1996) 134:1219-1227.
Schwartz et al., “Isolation and characterization of neural progenitor cells from post-mortem human cortex,” J. Neurosci. Res. (2003) 74:838-851.
Sudhof et al., “Synapsins: mosaics of shared and individual domains in a family of synaptic vesicle phosphoproteins,” Science (1989) 245:1474-1480.
Svendsen and Langston,“Stem cells for Parkinson disease and ALS: replacement or protection,” Nature Med. (2004) 10:224-225.
Toma, “Precise targeting in Parkinson's,” The Scientist (2003), .the-scientist.com
ews/20030331/03.
Valtorta et al., “Accelerated structural maturation induced by synapsina I at developing neuromuscular synapses of Xenopus laevis,” Eur. J. Neurosci. (1995) 7:261-270.
Vermeer et al., “Fucosylation of linear alcohols: a study of parameters influencing the stereochemistry of glycosylation,” Eur. J. Org. Chem. (2001) 2001:193-203.
Waugh, “Artificial skin for patient use,” Massachusettes Institute of Technology News Office, 1996, web.mit.edu
ewsoffice/1996.
Worthington Biochemical Corporation, Concanavalin A—Worthington Biochemical Product Catalog, Abstract only, found at www.worthington-biochem.com/CONA/cat.html (2008).
Gama Cristal I.
Hsieh-Wilson Linda C.
Kalovidouris Stacey
Bozicevic Field & Francis LLP
California Institute of Technology
Rutenberg Isaac M.
Saoud Christine J
Wang Chang-Yu
LandOfFree
Methods of inducing neuronal growth by a Fucose-α(1-2)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of inducing neuronal growth by a Fucose-α(1-2)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of inducing neuronal growth by a Fucose-α(1-2)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4238639